Evidence-graded research on heart and cardiovascular health — what trials and regulators show about omega-3, CoQ10 and other supplements, conflicts disclosed.
Key takeaways Best-supported use: statin-associated muscle pain — a meta-analysis of 12 RCTs (575 patients) found CoQ10 (100–200 mg/day) reduced statin-induced myalgia severity by ~30% (Qu et al., J Am Heart Assoc 2018). Moderate evidence: heart failure — the Q-SYMBIO trial (420 patients, 2 years) found 300 mg/day reduced major cardiovascular events by 43% in … Read more
Key takeaways D3 (cholecalciferol) raises and maintains blood 25(OH)D levels more effectively than D2 (ergocalciferol) — a meta-analysis of 24 RCTs confirmed higher potency of D3 per equivalent dose (Tripkovic et al., AJCN). Correcting deficiency (25(OH)D <20 ng/mL) has clear benefit; broad supplementation in already-replete adults for cancer, cardiovascular events, or major fractures showed no … Read more
Key takeaways Strongest evidence: modest triglyceride reduction (25–30% with 2–4 g/day EPA+DHA) and reduced cardiovascular events in secondary prevention at prescription doses — FDA has approved icosapent ethyl (EPA-only, 4 g) after the REDUCE-IT trial. For primary prevention of heart disease in the general population, effects are modest at best — a large Cochrane review … Read more
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
